Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $913.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by Royal Bank Of Canada from $810.00 to $913.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on REGN. Sanford C. Bernstein lifted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a research note on Friday, August 14th. Cantor Fitzgerald increased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an “overweight” rating in a research report on Monday. Evercore raised their price target on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. The Goldman Sachs Group boosted their price objective on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Piper Sandler upped their price objective on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an “overweight” rating in a research note on Monday, October 19th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $898.97.

Regeneron Pharmaceuticals Price Performance

REGN opened at $930.67 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. The stock’s 50 day simple moving average is $800.69 and its 200 day simple moving average is $741.11. The firm has a market cap of $95.82 billion, a price-to-earnings ratio of 20.38, a PEG ratio of 1.45 and a beta of 0.10. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue was up 36.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.83 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals will post 51.64 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.30%.

Insiders Place Their Bets

In other news, EVP Joseph Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the sale, the executive vice president owned 38,906 shares of the company’s stock, valued at approximately $37,563,353.94. The trade was a 10.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christine Poon sold 7,830 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the completion of the transaction, the director directly owned 5,219 shares of the company’s stock, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 20,789 shares of company stock worth $18,766,698. Company insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Lido Advisors LLC lifted its position in Regeneron Pharmaceuticals by 26.0% during the third quarter. Lido Advisors LLC now owns 14,677 shares of the biopharmaceutical company’s stock valued at $11,129,000 after purchasing an additional 3,030 shares during the period. Cornerstone Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter worth approximately $254,000. Csenge Advisory Group bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $237,000. Kestra Investment Management LLC grew its position in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 16 shares during the period. Finally, AlphaCore Capital LLC grew its position in Regeneron Pharmaceuticals by 133.5% in the 3rd quarter. AlphaCore Capital LLC now owns 1,602 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 916 shares during the period. Institutional investors own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.